Bifogade filer
Kurs & Likviditet
Kalender
2024-11-12 | Kvartalsrapport 2024-Q3 |
2024-08-13 | Kvartalsrapport 2024-Q2 |
2024-05-15 | Ordinarie utdelning MOB 0.00 SEK |
2024-05-14 | Årsstämma 2024 |
2024-05-07 | Kvartalsrapport 2024-Q1 |
2024-02-13 | Bokslutskommuniké 2023 |
2023-11-07 | Kvartalsrapport 2023-Q3 |
2023-10-09 | Extra Bolagsstämma 2023 |
2023-08-03 | Kvartalsrapport 2023-Q2 |
2023-05-24 | Split MOB 10:1 |
2023-05-17 | Ordinarie utdelning MOB 0.00 SEK |
2023-05-16 | Årsstämma 2023 |
2023-05-09 | Kvartalsrapport 2023-Q1 |
2023-02-07 | Bokslutskommuniké 2022 |
2022-11-08 | Kvartalsrapport 2022-Q3 |
2022-08-09 | Kvartalsrapport 2022-Q2 |
2022-05-17 | Ordinarie utdelning MOB 0.00 SEK |
2022-05-16 | Årsstämma 2022 |
2022-05-10 | Kvartalsrapport 2022-Q1 |
2022-05-03 | Extra Bolagsstämma 2022 |
2022-02-08 | Bokslutskommuniké 2021 |
2021-11-09 | Kvartalsrapport 2021-Q3 |
2021-08-10 | Kvartalsrapport 2021-Q2 |
2021-05-11 | Kvartalsrapport 2021-Q1 |
2021-03-31 | Ordinarie utdelning MOB 0.00 SEK |
2021-03-30 | Årsstämma 2021 |
2021-02-09 | Bokslutskommuniké 2020 |
2020-12-01 | Extra Bolagsstämma 2020 |
2020-05-12 | Kvartalsrapport 2020-Q3 |
2020-02-11 | Kvartalsrapport 2020-Q2 |
2019-11-19 | Kvartalsrapport 2020-Q1 |
2019-11-04 | Inlösen MOB 46.5 |
2019-10-31 | Ordinarie utdelning MOB 0.00 SEK |
2019-10-30 | Årsstämma 2020 |
2019-08-29 | Bokslutskommuniké 2019 |
2019-05-16 | Ordinarie utdelning MOB 0.00 SEK |
2019-05-15 | Årsstämma 2019 |
2019-05-14 | Kvartalsrapport 2019-Q1 |
2019-03-15 | Extra Bolagsstämma 2019 |
2019-02-12 | Bokslutskommuniké 2018 |
2018-11-06 | Kvartalsrapport 2018-Q3 |
2018-08-07 | Kvartalsrapport 2018-Q2 |
2018-05-16 | Ordinarie utdelning MOB 0.00 SEK |
2018-05-15 | Årsstämma 2018 |
2018-05-08 | Kvartalsrapport 2018-Q1 |
2018-02-13 | Bokslutskommuniké 2017 |
2017-11-13 | Kvartalsrapport 2017-Q3 |
2017-08-08 | Kvartalsrapport 2017-Q2 |
2017-05-17 | Ordinarie utdelning MOB 0.00 SEK |
2017-05-16 | Årsstämma 2017 |
2017-05-09 | Kvartalsrapport 2017-Q1 |
2017-02-14 | Bokslutskommuniké 2016 |
2016-11-08 | Kvartalsrapport 2016-Q3 |
2016-08-09 | Kvartalsrapport 2016-Q2 |
2016-05-19 | Ordinarie utdelning MOB 0.00 SEK |
2016-05-18 | Årsstämma 2016 |
2016-05-10 | Kvartalsrapport 2016-Q1 |
2016-02-17 | Bokslutskommuniké 2015 |
2015-11-10 | Kvartalsrapport 2015-Q3 |
2015-08-11 | Kvartalsrapport 2015-Q2 |
2015-05-12 | Ordinarie utdelning MOB 0.00 SEK |
2015-05-11 | Årsstämma 2015 |
2015-05-11 | Bokslutskommuniké 2014 |
2015-05-11 | Kvartalsrapport 2015-Q1 |
2015-02-27 | Bokslutskommuniké 2014 |
2014-11-14 | Kvartalsrapport 2014-Q3 |
2014-08-13 | Kvartalsrapport 2014-Q2 |
2014-05-14 | Ordinarie utdelning MOB 0.00 SEK |
2014-05-13 | Årsstämma 2014 |
2014-05-13 | Kvartalsrapport 2014-Q1 |
2014-02-20 | Bokslutskommuniké 2013 |
2013-11-05 | Kvartalsrapport 2013-Q3 |
2013-08-06 | Kvartalsrapport 2013-Q2 |
2013-05-21 | Kvartalsrapport 2013-Q1 |
2013-05-21 | Analytiker möte 2013 |
2013-04-24 | Ordinarie utdelning MOB 0.00 SEK |
2013-04-23 | Årsstämma 2013 |
2013-03-13 | 15-7 2013 |
2013-02-05 | Bokslutskommuniké 2012 |
2012-11-19 | Extra Bolagsstämma 2012 |
2012-10-25 | Kvartalsrapport 2012-Q3 |
2012-09-20 | Kapitalmarknadsdag 2012 |
2012-08-28 | Kvartalsrapport 2012-Q2 |
2012-06-11 | 15-7 2012 |
2012-04-24 | Ordinarie utdelning MOB 0.00 SEK |
2012-04-23 | Årsstämma 2012 |
2012-04-23 | Kvartalsrapport 2012-Q1 |
2012-02-09 | Bokslutskommuniké 2011 |
2011-11-29 | 15-7 2011 |
2011-10-28 | Kvartalsrapport 2011-Q3 |
2011-08-12 | Kvartalsrapport 2011-Q2 |
2011-04-18 | Kvartalsrapport 2011-Q1 |
Beskrivning
Land | Sverige |
---|---|
Lista | Small Cap Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
Moberg Pharma AB (publ) has submitted regulatory filing for the next clinical Phase 3 study for MOB-015 (nail fungus treatment) to the U.S. Food and Drug Administration (FDA).
The randomized, multicenter, vehicle-controlled Phase 3 study will include approximately 350 patients in North America. The patients will be evaluated over 52 weeks and the primary endpoint will be the proportion of subjects achieving complete cure of their target nail. The company expects to start enrolling patients in the second quarter of this year. The study design builds on the experience gained from the previous Phase 3 studies. Moberg Pharma will cooperate with the same CRO, lead investigator and successful sites from the previous North American study. The purpose of the new study is to facilitate market approval in the US as well as strengthen the product's clinical evidence and marketing claims globally.
"For market approval in the U.S., the FDA typically requires two studies that demonstrate statistical superiority of the active drug versus its vehicle (placebo) for the primary endpoint. The first study was successfully completed in 2019 and we are now conducting the second study. The North American study is a top priority in the near future, in addition to the registration process in Europe where our goal is to receive first market approval and launch in 2023", says Anna Ljung, CEO of Moberg Pharma AB.
Anna Ljung, CEO, telephone: +46 707 66 60 30, e-mail: anna.ljung@mobergpharma.se
About this information
The information was submitted for publication, through the agency of the contact persons set out above, at 8.00 a.m. CET on March 18[th], 2022.